EA201391288A1 - Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз - Google Patents

Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз

Info

Publication number
EA201391288A1
EA201391288A1 EA201391288A EA201391288A EA201391288A1 EA 201391288 A1 EA201391288 A1 EA 201391288A1 EA 201391288 A EA201391288 A EA 201391288A EA 201391288 A EA201391288 A EA 201391288A EA 201391288 A1 EA201391288 A1 EA 201391288A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
acetyl
pyrazolospirocetones
coa
derivatives
Prior art date
Application number
EA201391288A
Other languages
English (en)
Other versions
EA022375B1 (ru
Inventor
Дэвид Эндрю Гриффит
Роберт Ли Доу
Джеймс Альфред мл. Саутерс
Дейвид Джеймс Эдмондс
Original Assignee
Пфайзер Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Пфайзер Инк. filed Critical Пфайзер Инк.
Publication of EA201391288A1 publication Critical patent/EA201391288A1/ru
Publication of EA022375B1 publication Critical patent/EA022375B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Photographic Processing Devices Using Wet Methods (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Согласно изобретению предложены соединение формулы (I)или его фармацевтически приемлемая соль; где G представляет собой (II)или (III)R, Rи Rявляются такими, как изложено в данной заявке; их фармацевтические композиции и их применение в лечении заболеваний, состояний или расстройств, модулируемых посредством ингибирования фермента(ов), представляющего(их) собой ацетил-КоА-карбоксилазу(ы), у животного.
EA201391288A 2011-04-22 2012-04-09 ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ EA022375B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478240P 2011-04-22 2011-04-22
PCT/IB2012/051732 WO2012143813A1 (en) 2011-04-22 2012-04-09 Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors

Publications (2)

Publication Number Publication Date
EA201391288A1 true EA201391288A1 (ru) 2014-04-30
EA022375B1 EA022375B1 (ru) 2015-12-30

Family

ID=46025823

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391288A EA022375B1 (ru) 2011-04-22 2012-04-09 ПРОИЗВОДНЫЕ ПИРАЗОЛОСПИРОКЕТОНОВ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ АЦЕТИЛ-КоА-КАРБОКСИЛАЗ

Country Status (41)

Country Link
US (4) US8802688B2 (ru)
EP (1) EP2699576B1 (ru)
JP (1) JP5657174B2 (ru)
KR (1) KR101567659B1 (ru)
CN (2) CN103492388A (ru)
AP (1) AP3499A (ru)
AR (1) AR086198A1 (ru)
AU (1) AU2012245996B2 (ru)
CA (1) CA2831380C (ru)
CL (1) CL2013002794A1 (ru)
CO (1) CO6801757A2 (ru)
CR (1) CR20130464A (ru)
CU (1) CU24164B1 (ru)
CY (1) CY1117122T1 (ru)
DK (1) DK2699576T3 (ru)
DO (1) DOP2013000243A (ru)
EA (1) EA022375B1 (ru)
EC (1) ECSP13013038A (ru)
ES (1) ES2561452T3 (ru)
GE (1) GEP20166474B (ru)
GT (1) GT201300258A (ru)
HR (1) HRP20151397T1 (ru)
HU (1) HUE028602T2 (ru)
IL (1) IL228949A (ru)
MA (1) MA35061B1 (ru)
ME (1) ME02312B (ru)
MX (1) MX348860B (ru)
MY (1) MY162167A (ru)
NI (1) NI201300111A (ru)
NZ (1) NZ616156A (ru)
PE (1) PE20141187A1 (ru)
PL (1) PL2699576T3 (ru)
PT (1) PT2699576E (ru)
RS (1) RS54526B1 (ru)
SG (1) SG194142A1 (ru)
SI (1) SI2699576T1 (ru)
TN (1) TN2013000393A1 (ru)
TW (1) TWI464171B (ru)
UA (1) UA107753C2 (ru)
UY (1) UY34027A (ru)
WO (1) WO2012143813A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102336C2 (ru) * 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПИРАЗОЛСПИРОКЕТОНЫ КАК ИНГИБИТОРЫ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
CN102491974B (zh) * 2011-12-12 2013-08-07 南京药石药物研发有限公司 1-（2-氟苄基）-1H-吡唑并[3，4-b]吡啶-3-甲脒盐酸盐的合成方法
TWI630194B (zh) 2013-03-14 2018-07-21 凱立拉製藥公司 雙環止痛化合物
CN105358154A (zh) 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
KR20160005365A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
CN105530940A (zh) * 2013-09-12 2016-04-27 辉瑞大药厂 乙酰辅酶a羧化酶抑制剂用于治疗寻常痤疮的用途
EP3670496A3 (en) 2013-10-17 2020-09-30 Shionogi&Co., Ltd. Acc2 inhibitors
KR102380609B1 (ko) 2013-12-12 2022-03-30 리커리엄 아이피 홀딩스, 엘엘씨 바이사이클릭 알킬 화합물 및 합성
KR102401840B1 (ko) * 2014-03-07 2022-05-25 리커리엄 아이피 홀딩스, 엘엘씨 프로펠란 유도체 및 합성
CA2892342C (en) 2014-05-22 2016-11-01 Sylvain-Paul Morency Tool and method for layer depalletizing
WO2016044331A1 (en) 2014-09-17 2016-03-24 Kalyra Pharmaceuticals, Inc. Bicyclic compounds
CA3010097C (en) * 2015-12-31 2023-08-22 Institute Of Materia Medica, Chinese Academy Of Medical Sciences Application of triacetyl-3-hydroxyphenyladenosine in preparation of pharmaceutical drug for preventing or treating non-alcoholic fatty liver disease
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
US11242327B2 (en) 2017-05-15 2022-02-08 Recurium Ip Holdings, Llc Analgesic compounds
ES2942463T3 (es) * 2017-11-21 2023-06-01 Pfizer Sal cristalina 2-amino-2-(hidroximetil)propano-1,3-diol del ácido 4-(4-(1-isopropil-7-oxo-1,4,6,7-tetrahidroespiro[indazol-5,4'-piperidina]-1'-carbonil)-6-metoxipiridin-2-il)benzoico
CN111574530B (zh) * 2020-04-21 2022-07-26 徐州医科大学 一种acc抑制剂及其医药用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0901786B1 (en) 1997-08-11 2007-06-13 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
GEP20053710B (en) 2001-02-28 2005-12-26 Merck & Co Inc Acylated Piperidine Derivatives as Melanocortin-4 Receptor Agonists
ES2246481T3 (es) 2002-02-27 2006-02-16 Pfizer Products Inc. Inhibidores de la acc.
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
WO2004092179A1 (ja) 2003-04-14 2004-10-28 Nippon Soda Co. Ltd. スピロ誘導体、製造法および抗酸化薬
JP2005119987A (ja) 2003-10-15 2005-05-12 Ajinomoto Co Inc アシルスルホンアミド誘導体
AU2005247684B2 (en) 2004-05-12 2008-10-23 Pfizer Products Inc. Proline derivatives and their use as dipeptidyl peptidase IV inhibitors
WO2005113069A2 (en) 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
CN1950374A (zh) 2004-05-25 2007-04-18 辉瑞产品公司 四氮杂苯并[e]甘菊环衍生物及其类似物
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
AU2006270145B2 (en) 2005-07-19 2011-04-14 Msd K.K. Spirochromanone derivatives as acetyl coenzyme a carboxylase (ACC) inhibitors
CA2617042A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Spiro-cyclic compound
AU2006316626A1 (en) 2005-11-18 2007-05-31 Merck Sharp & Dohme Corp. Spirohydantoin aryl CGRP receptor antagonists
EP1991536A2 (en) 2006-02-15 2008-11-19 Abbott Laboratories Novel acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome
NL2000581C2 (nl) 2006-04-20 2008-01-03 Pfizer Prod Inc Aangecondenseerde fenylamidoheterocyclische verbindingen.
KR20090083956A (ko) 2006-11-29 2009-08-04 화이자 프로덕츠 인크. 스피로케톤 아세틸-ＣｏＡ 카르복실라제 억제제
PE20081559A1 (es) 2007-01-12 2008-11-20 Merck & Co Inc DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA
EP2123652A1 (en) * 2007-02-20 2009-11-25 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN104356136A (zh) 2007-04-12 2015-02-18 辉瑞大药厂 作为蛋白酶c抑制剂的3-酰氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
US20090036425A1 (en) 2007-08-02 2009-02-05 Pfizer Inc Substituted bicyclolactam compounds
US7981904B2 (en) 2008-03-20 2011-07-19 Takeda Pharmaceutical Company Limited Acetyl CoA carboxylase inhibitors
CA2724603A1 (en) 2008-05-28 2009-12-03 Pfizer Inc. Pyrazolospiroketone acetyl-coa carboxylase inhibitors
ES2545231T3 (es) * 2008-05-28 2015-09-09 Pfizer Inc. Inhibidores de pirazoloespirocetona acetil-CoA carboxilasa
WO2010002010A1 (en) * 2008-07-04 2010-01-07 Banyu Pharmaceutical Co.,Ltd. Novel spirochromanone carboxylic acids
WO2010008521A1 (en) 2008-07-14 2010-01-21 Cropsolution, Inc. Modulators of acetyl-coenzyme a carboxylase and methods of use thereof
CA2729581A1 (en) 2008-07-29 2010-02-04 Pfizer Inc. Fluorinated heteroaryls
BRPI0918841B8 (pt) 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
TW201038580A (en) 2009-02-02 2010-11-01 Pfizer 4-amino-5-oxo-7,8-dihydropyrimido[5,4-f][1,4]oxazepin-6(5H)-yl)phenyl derivatives
GEP20156239B (en) 2009-03-11 2015-01-26 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
US20110319379A1 (en) 2009-03-11 2011-12-29 Corbett Jeffrey W Substituted Indazole Amides And Their Use As Glucokinase Activators
US20120095028A1 (en) 2009-03-20 2012-04-19 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
WO2010128414A1 (en) 2009-05-08 2010-11-11 Pfizer Inc. Gpr 119 modulators
EP2427450A1 (en) 2009-05-08 2012-03-14 Pfizer Inc. Gpr 119 modulators
EP2438051A1 (en) 2009-06-05 2012-04-11 Pfizer Inc. L- ( piperidin-4-yl) -pyrazole derivatives as gpr 119 modulators
WO2011005611A1 (en) 2009-07-09 2011-01-13 Merck Sharp & Dohme Corp. Neuromedin u receptor agonists and uses thereof
UA102336C2 (ru) * 2009-11-10 2013-06-25 Пфайзер Інк. N1-ПИРАЗОЛСПИРОКЕТОНЫ КАК ИНГИБИТОРЫ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ
US20120225900A1 (en) * 2009-11-10 2012-09-06 Pfizer Inc. N2-pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT2621493T (pt) * 2010-09-30 2016-11-14 Pfizer Inibidores de n1-pirazolospirocetona acetil-coa carboxilase

Also Published As

Publication number Publication date
EA022375B1 (ru) 2015-12-30
WO2012143813A1 (en) 2012-10-26
CY1117122T1 (el) 2017-04-05
CN106117205A (zh) 2016-11-16
HUE028602T2 (hu) 2016-12-28
CN106117205B (zh) 2018-09-21
GT201300258A (es) 2015-06-02
US20120270893A1 (en) 2012-10-25
KR20140015511A (ko) 2014-02-06
NZ616156A (en) 2014-08-29
CA2831380C (en) 2016-04-05
MX348860B (es) 2017-06-30
EP2699576B1 (en) 2015-12-09
JP2014515755A (ja) 2014-07-03
DOP2013000243A (es) 2013-12-31
ES2561452T3 (es) 2016-02-26
AU2012245996A1 (en) 2013-10-03
CN103492388A (zh) 2014-01-01
HRP20151397T1 (hr) 2016-01-15
PE20141187A1 (es) 2014-09-18
MX2013012313A (es) 2014-01-31
CU24164B1 (es) 2016-03-31
PL2699576T3 (pl) 2016-05-31
RS54526B1 (en) 2016-06-30
DK2699576T3 (en) 2016-02-15
JP5657174B2 (ja) 2015-01-21
MA35061B1 (fr) 2014-04-03
UA107753C2 (xx) 2015-02-10
AP3499A (en) 2015-12-31
US8802688B2 (en) 2014-08-12
SG194142A1 (en) 2013-11-29
UY34027A (es) 2013-04-05
ME02312B (me) 2016-06-20
TW201305162A (zh) 2013-02-01
PT2699576E (pt) 2016-03-09
CL2013002794A1 (es) 2013-12-27
IL228949A (en) 2016-11-30
NI201300111A (es) 2014-02-12
US20140323730A1 (en) 2014-10-30
TN2013000393A1 (fr) 2015-01-20
US20150112068A1 (en) 2015-04-23
GEP20166474B (en) 2016-05-10
SI2699576T1 (sl) 2016-02-29
AP2013007129A0 (en) 2013-09-30
CA2831380A1 (en) 2012-10-26
TWI464171B (zh) 2014-12-11
AU2012245996B2 (en) 2016-09-01
AR086198A1 (es) 2013-11-27
CR20130464A (es) 2013-10-16
CO6801757A2 (es) 2013-11-29
EP2699576A1 (en) 2014-02-26
CU20130126A7 (es) 2014-01-29
US20150336958A1 (en) 2015-11-26
IL228949A0 (en) 2013-12-31
KR101567659B1 (ko) 2015-11-09
ECSP13013038A (es) 2014-01-31
MY162167A (en) 2017-05-31

Similar Documents

Publication Publication Date Title
EA201391288A1 (ru) Производные пиразолоспирокетонов для применения в качестве ингибиторов ацетил-коа-карбоксилаз
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
EA201300684A1 (ru) Производные 6-амино-2-фениламино-1н-бензимидазол-5-карбоксамида и их применение в качестве ингибиторов микросомной простагландин-е2-синтазы-1
EA201390917A1 (ru) Дигетероарильные соединения в качестве ингибиторов vps34
EA201290980A1 (ru) Производные 1-амино-2-циклопропилэтилбороновой кислоты
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
EA201390723A1 (ru) Аминозамещенные производные бисфенилпентановой кислоты в качестве ингибиторов nep
EA201590975A1 (ru) Ингибиторы prmt5 и их применение
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201390711A1 (ru) Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения
UA111770C2 (uk) Інгібітори бромдомену
EA201101026A1 (ru) Ингибиторы бета-секретазы
MY172924A (en) Neprilysin inhibitors
EA201101671A1 (ru) Замещенные производные аминопропионовой кислоты в качестве ингибиторов неприлизина
EA201400358A1 (ru) Замещенные n-[1-циано-2-(фенил)этил]-2-азабицикло[2.2.1]гептан-3-карбоксамидные ингибиторы катепсина с
EA201390347A1 (ru) Лечение заболеваний
EA201690129A1 (ru) Гетероарильные соединения, пригодные в качестве ингибиторов sumo-активирующего фермента
EA201490471A1 (ru) Пиридазиноновые соединения и их применение в качестве ингибиторов daao
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
EA201500182A1 (ru) 4-МЕТИЛ-2,3,5,9,9b-ПЕНТААЗАЦИКЛОПЕНТА[a]НАФТАЛИНЫ
EA201300250A1 (ru) Оксадиазольные ингибиторы продуцирования лейкотриена
EA201300436A8 (ru) Совместные кристаллы и соли ингибиторов ccr3

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU